Clorpheniramin 4mg ch/200

Print
Barcode:
Description

COMPOSITION:
Chlorpheniramine maleate ........4 mg
Excipients q.s........................1 tablet
(Quinoline color, lactose, tapioca starch, aerosil, magnesium stearate, talc, gelatin)
DOSAGE FORM: Tablets.
PRESENTATION: Box of 10 blisters x 20 tablets.     Box of 1 bottle x 200 tablets.
ACTIONS: Chlorpheniramine is an anti-histamine which antagonizes competitively and reversibly to histamine H1-receptors.
Chlorpheniramine maleate is well absorbed by oral administration and occurs for 30 to 60 minutes in the plasma, peak plasma concentrations occurring about 2.5 to 6 hours. About 70% of Chlorpheniramine in the circulation is bound to plasma proteins. Unchanged drug and active metabolites are excreted primarily in the urine; excretion is dependent on urinary pH and flow-rate. The half-life is about 12 to 15 hours.
INDICATIONS: Allergic rhinitis, rhinorrhea, nasal stuffiness, coryza.
Other allergic symptoms such as urticaria, contact dermatitis, pruritus, food allergy, insect bites, allergic conjunctivitis, Quincke's edema.
CONTRAINDICATIONS:
Hypersensitivity to Chlorpheniramine and any components of the drug.
Closed-angle glaucoma, prostatauxe, bladder outlet obstruction. Gastric ulcer, duodenal and pyloric obstruction. Patients suffering from acute asthma. Nursing mothers, neonates and premature infants. Individuals receiving MAOIs within 14 days from the day starting treatment with Chlorpheniramine. 
PRECAUTIONS: Chlorpheniramine may cause an increase in urinary retention, particularly in the individuals who suffered from prostatauxe, urinary tract obstruction, duodenal and pyloric obstruction, myasthenia gravis. The sedative effect of chlorpheniramine may be increased when it is concurrently used with alcoholic drinks or other sedative agents. Use with cautions in patients with chronic pulmonary disease, shortness of breath or breathing difficulty due to the risk of respiratory complications, respiratory failure and apnoea. Prolonged use of Chlorpheniramine may cause a risk of dental caries. Avoid using for the patients suffered from glaucoma. Use with cautions in the elderly.
PREGNANCY AND LACTATION: Chlorpheniramine is only indicated to pregnant women if clearly needed. Do not take it in the last trimester of pregnancy.
Take the drug and stop breast-feeding or do not take the drug should be considered depending on the necessary.
VEHICLE DRIVERS AND MACHINERY OPERATORS:
Avoid giving the drug to these subjects.
INTERACTIONS: Chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity. Narcotic tranquillizers, alcoholic drinks may increase the effect of CNS inhibition of Chlorpheniramine. The anticholinergic effects of anti-histamine agents are intensified and prolonged by MAOIs.  
ADVERSE EFFECTS: Common: Drowsiness, sedation, dryness of mouth
Rare:  Dizziness, nausea
Inform your physician about any adverse effects occur during the treatment.
OVERDOSAGE: Fatal dose: 25 - 50 mg/kg of body-weight
Symptoms of overdosage include, psychosis, epilepsy, apnoea, convulsion, antiacetylcholine action, dystonia, heart attack, arrhythmia.
Treatment: Gastric lavage or conduction of vomiting with Ipecacuanha syrup; then, using activated carbon or cathartic to limit absorption. Full supportive measures should also be instituted in case of hypotension and arrhythmia. Convulsions may be treated by intravenous injection of Diazepam or Phenytoin. Blood transfusion may be practiced in severe cases.
DOSAGE & ADMINISTRATION: Adults and children aged > 12 years: 1 tablet at bed time. Do not exceed 6 tablets a day.
The elderly: oral dose of 4 mg in two divided doses a day.
Or as directed by the physician.
        Read the directions carefully before use.
        Consult the physician for more information.
Shelf-life: 36 months from the manufacturing date.
Storage conditions: Store in dry places, not exceeding 30oC,
                                          protect from light.
Specifications: Manufacturer's.

Reviews

There are yet no reviews for this product.